Spain's Rx spending rises 12% in March

30 April 2006

Spain's prescription drugs bill in March rose 12% to 893.6 million euros ($1.1 billion) on the back of fewer drug discounts and a longer billing period, the Health Ministry has announced. Average prescription costs rose 0.77%, pushing the interannual (last 12 months) rate to 0.75%, it noted.

Prescription volumes rose to 69.7 million, up 11.23% from the previous year period, according to the Ministry. Unlike last year, the Easter Holiday took place in April, extending the March sales period, the Ministry said, explaining the reasons behind the expense hike as being that, last year, the government applied a 4.2% drug discount while this year it has totalled 2%.

State health spending curb "is working"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight